amphetamine has been researched along with pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Illes, P; Kittner, H; Krügel, U | 1 |
| Franke, H; Illes, P; Kittner, H; Krügel, U | 1 |
2 other study(ies) available for amphetamine and pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid
| Article | Year |
|---|---|
The purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4'-disulphonic acid prevents both the acute locomotor effects of amphetamine and the behavioural sensitization caused by repeated amphetamine injections in rats.
Topics: Adenosine Triphosphate; Amphetamine; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Antagonism; Injections, Intraventricular; Male; Motor Activity; Purinergic P2 Receptor Antagonists; Pyridoxal Phosphate; Rats; Rats, Wistar; Receptors, Purinergic P2 | 2001 |
Stimulation of P2 receptors in the ventral tegmental area enhances dopaminergic mechanisms in vivo.
Topics: Adenosine Triphosphate; Amphetamine; Animals; Dopamine; Dopamine Uptake Inhibitors; Male; Motor Activity; Neurons; Platelet Aggregation Inhibitors; Pyridoxal Phosphate; Rats; Rats, Wistar; Receptors, Purinergic P2; Thionucleotides; Ventral Tegmental Area | 2001 |